Associate Director of Tax at Corcept Therapeutics

Redwood City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Bachelor’s degree in Accounting or Finance and CPA required, Master’s in Taxation is a plus
At least 10 years of progressive experience in tax
Experience in biotech/pharmaceutical environment is preferred
Demonstrated experience with U.S. GAAP tax provision and SOX
Detailed knowledge of GAAP and SEC reporting requirements related to income taxes and related disclosures
Detailed knowledge of income tax return filing requirements in a multistate reporting environment
Tax research skills
International tax and transfer pricing experience
Strong attention to detail and organizational skills
Ability to prioritize work and meet deadlines
Ability to work efficiently with minimal supervision and in a team environment
Strong leadership and collaboration skills
Excellent interpersonal, communication, and organizational skills
Proficient computer skills and knowledge of Microsoft Office Suite (Excel, Word, Outlook, etc.)
Currently authorized to work in the United States on a full-time basis

Responsibilities

Maintain tax and regulatory compliance across local, state, federal, and international jurisdictions, including income, sales and use, property, and VAT taxes
Review quarterly income tax provisions in accordance with ASC 740 and maintain uncertain tax positions under FIN 48
Review federal and state R&D tax credit calculations
Perform monthly tax close processes, including journal entries and account reconciliations
Support internal and external audits, including Sarbanes-Oxley Section 404 compliance related to tax
Lead federal, state, and international tax planning initiatives
Develop transfer pricing policies and documentation, including intercompany agreements, to ensure compliance with global and local tax regulations
Ensure timely filing of all tax and regulatory returns (e.g., quarterly estimates, annual extensions, and income tax returns)
Manage VAT compliance, including refunds, reconciliations, and registrations in new jurisdictions as needed
File property tax returns
File annual reports with Secretary of State offices
Monitor and analyze changes in domestic and international tax laws and regulations, assessing the impact on the Company and recommending proactive responses
Collaborate cross-functionally with Finance, Legal, and Operations teams to support business planning and decision-making from a tax perspective

Skills

GAAP

ASC 740

FIN 48

SOX 404

R&D Tax Credits

Transfer Pricing

VAT Compliance

Tax Planning

Journal Entries

Account Reconciliations

Income Tax Provision

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free